2021, Number 1
<< Back Next >>
Med Int Mex 2021; 37 (1)
Frequency of anosmia and dysgeusia in patients hospitalized with SARS-CoV-2
Díaz-Reyna D, Pineda-Cásares F, Andrade-Galicia A, Aguilar-García CR, Gutiérrez-Ortiz M, Gelover-Manzo R
Language: Spanish
References: 10
Page: 56-61
PDF size: 443.56 Kb.
ABSTRACT
Objective: To determine the frequency of anosmia and dysgeusia in hospitalized
patients with diagnosis of acute respiratory failure, secondary to atypical pneumonia
due to COVID-19.
Materials and Methods: Prospective, descriptive-transverse and analytical study,
done from 25 April to 3 June 2020, in patients who had anosmia and dysgeusia diagnosed
with secondary respiratory failure to atypical pneumonia with confirmed COVID-
19 test, with a detailed medical history at their admission and during their hospital
stay, with emphasis on the presence of anosmia, dysgeusia and their clinical evolution.
Results: Out of the total of 205 hospitalized patients diagnosed with acute respiratory
failure, secondary to probable atypical pneumonia COVID-19, only 141 (68.7%) had
anosmia and dysgeusia and had positive PCR testing for COVID-19, of which 92 cases
were male (65.2%) and 49 cases (34.7%) female. In 85 patients (60.3%) anosmia and
dysgeusia were their first clinical manifestation. Their evolution was: in 115 (81.5%)
both clinical manifestations disappeared in an average of 10 days; 112 patients (79.4%)
had concomitant diseases and during the study 12 patients (8.5%) died.
Conclusions: Anosmia and dysgeusia are part of the important symptoms of COVID-
19, particularly in the early stage of the disease. Its early detection is a valuable tool
for early diagnosis and effective treatment that will impact on morbidity and mortality.
REFERENCES
Organización Panamericana de la Salud/Organización Mundial de la Salud. Actualización Epidemiológica: Nuevo coronavirus (COVID-19). Washington DC: OPS/ OMS; 2020: 1.
Spinato G, Fabbris C, Polesel J, Cazzador D, et al. Alterations in smell or taste in midly symptomatic outpatients with SARS-CoV-2 infection. JAMA 2020; 323 (20): 2089-2090. doi. 10.1001/jama.2020.6771.
Alberini B. Disfunciones olfativas y gustativas como presentación clínica de formas leves a moderadas de la enfermedad por coronavirus (COVID-19): un estudio europeo multicéntrico. Eur Arch Otorhinolaryngol 2020;6 (10): 4-6.
Zimmermann P, Curtis, N, Covid-19 in children, pregnancy and neonates: A review of epidemiologic and clinical features. Pediatr Infect Dis J 2020. doi. 10.1097/ INF.0000000000002700.
Yonghyun L, Pokee M. Prevalence and duration of acute loss of smell or taste in Covid-19 patients. J Korean Med Sci. 2020. doi. 10.3346/jkms.2020.35.e174.
Le Bon S, et al. Is anosmia the price to pay in an immune-induced scorched-earth policy against Covid 19? Med Hypotheses 2020; 17 (34): 1-2. doi. 10.1016/j.mehy.2020.109881.
Vaira LA, Hopkins C, Salzano G, Petrocelli M, et al. Olfactory and gustatory function impairment in Covid-19 patients: Italian objective multicenter-study. Head Neck 2020; 10 (08): 2-4. https://doi.org/10.1002/hed.26269.
Beltran A, Chico JL, Martínez J, Rodríguez F, et al. Acuteonset smell and taste disorders in the context of Covid-19: a pilot multicenter PCR – based case -control study. Eur J Neurol. 2020; 4 (5): 2-3. https://doi.org/10.1111/ ene.14273.
Menni C, Valdes A. Real-time tracking of self -reported symptoms to predict potential COVID -19. Nature Med 2020; 9 (27): 4.
Jerome R, Lechien M, Barillari M. Anosmia is a key symptom of Covid-19 infection and should be used as a diagnostic tool. Ear Nose Throat J 2020; 1: 6. https://doi. org/10.1177%2F0145561320925191
Full text